Danusertib CML Chronic Myeloid Leukemia
Danusertib is a potent inhibitor of Aurora kinases and Abl (including T315I mutation resistant to approved agents in CML).
ARTICLES
A Phase I Study Of Danusertib (PHA-739358) In Adult Patients With Accelerated Or Blastic Phase Chronic Myeloid Leukemia And Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant Or Intolerant To Imatinib And/Or Other Second Generation C-ABL Therapy
July 2015, Haematologica
Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).
June 21, 2012, PublMed
Moffitt researcher investigates 2-drug synergy to treat drug-resistant chronic myeloid leukemia
October 24, 2012, EurekAlert
Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
2010, PublMed
A Phase I Study Of Danusertib (PHA-739358) In Adult Patients With Accelerated Or Blastic Phase Chronic Myeloid Leukemia And Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant Or Intolerant To Imatinib And/Or Other Second Generation C-ABL Therapy
July 2015, Haematologica
Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).
June 21, 2012, PublMed
Moffitt researcher investigates 2-drug synergy to treat drug-resistant chronic myeloid leukemia
October 24, 2012, EurekAlert
Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
2010, PublMed
